Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity.

Hoves S, Ooi CH, Wolter C, Sade H, Bissinger S, Schmittnaegel M, Ast O, Giusti AM, Wartha K, Runza V, Xu W, Kienast Y, Cannarile MA, Levitsky H, Romagnoli S, De Palma M, Rüttinger D, Ries CH.

J Exp Med. 2018 Mar 5;215(3):859-876. doi: 10.1084/jem.20171440. Epub 2018 Feb 7.

2.

A drug development perspective on targeting tumor-associated myeloid cells.

Majety M, Runza V, Lehmann C, Hoves S, Ries CH.

FEBS J. 2018 Feb;285(4):763-776. doi: 10.1111/febs.14277. Epub 2017 Oct 19. Review.

3.

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AH, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanovello P, Molon B, Ries CH, Runza V, Hoves S, Bilocq AM, Bindea G, Mazza EM, Bicciato S, Galon J, Murray PJ, Bronte V.

Cancer Cell. 2016 Oct 10;30(4):651. doi: 10.1016/j.ccell.2016.09.009. No abstract available.

4.

T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.

Marigo I, Zilio S, Desantis G, Mlecnik B, Agnellini AHR, Ugel S, Sasso MS, Qualls JE, Kratochvill F, Zanovello P, Molon B, Ries CH, Runza V, Hoves S, Bilocq AM, Bindea G, Mazza EMC, Bicciato S, Galon J, Murray PJ, Bronte V.

Cancer Cell. 2016 Sep 12;30(3):377-390. doi: 10.1016/j.ccell.2016.08.004. Erratum in: Cancer Cell. 2016 Oct 10;30(4):651.

5.

Targeting Tumor Cells with Anti-CD44 Antibody Triggers Macrophage-Mediated Immune Modulatory Effects in a Cancer Xenograft Model.

Maisel D, Birzele F, Voss E, Nopora A, Bader S, Friess T, Goller B, Laifenfeld D, Weigand S, Runza V.

PLoS One. 2016 Jul 27;11(7):e0159716. doi: 10.1371/journal.pone.0159716. eCollection 2016.

6.

Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia.

Vey N, Delaunay J, Martinelli G, Fiedler W, Raffoux E, Prebet T, Gomez-Roca C, Papayannidis C, Kebenko M, Paschka P, Christen R, Guarin E, Bröske AM, Baehner M, Brewster M, Walz AC, Michielin F, Runza V, Meresse V, Recher C.

Oncotarget. 2016 May 31;7(22):32532-42. doi: 10.18632/oncotarget.8687.

7.

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.

Brünker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller CF, Weiser B, Majety M, Runza V, Niu H, Packman K, Feng N, Daouti S, Hosse RJ, Mössner E, Weber TG, Herting F, Scheuer W, Sade H, Shao C, Liu B, Wang P, Xu G, Vega-Harring S, Klein C, Bosslet K, Umaña P.

Mol Cancer Ther. 2016 May;15(5):946-57. doi: 10.1158/1535-7163.MCT-15-0647. Epub 2016 Apr 1.

8.

Reversion to an embryonic alternative splicing program enhances leukemia stem cell self-renewal.

Holm F, Hellqvist E, Mason CN, Ali SA, Delos-Santos N, Barrett CL, Chun HJ, Minden MD, Moore RA, Marra MA, Runza V, Frazer KA, Sadarangani A, Jamieson CH.

Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15444-9. doi: 10.1073/pnas.1506943112. Epub 2015 Nov 30.

9.

CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients.

Birzele F, Voss E, Nopora A, Honold K, Heil F, Lohmann S, Verheul H, Le Tourneau C, Delord JP, van Herpen C, Mahalingam D, Coveler AL, Meresse V, Weigand S, Runza V, Cannarile M.

Clin Cancer Res. 2015 Jun 15;21(12):2753-62. doi: 10.1158/1078-0432.CCR-14-2141. Epub 2015 Mar 11.

10.

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.

Ries CH, Cannarile MA, Hoves S, Benz J, Wartha K, Runza V, Rey-Giraud F, Pradel LP, Feuerhake F, Klaman I, Jones T, Jucknischke U, Scheiblich S, Kaluza K, Gorr IH, Walz A, Abiraj K, Cassier PA, Sica A, Gomez-Roca C, de Visser KE, Italiano A, Le Tourneau C, Delord JP, Levitsky H, Blay JY, Rüttinger D.

Cancer Cell. 2014 Jun 16;25(6):846-59. doi: 10.1016/j.ccr.2014.05.016. Epub 2014 Jun 2.

11.

Immature mouse granulocytic myeloid cells are characterized by production of ficolin-B.

Weber-Steffens D, Hunold K, Kürschner J, Martinez SG, Elumalai P, Schmidt D, Trevani A, Runza VL, Männel DN.

Mol Immunol. 2013 Dec;56(4):488-96. doi: 10.1016/j.molimm.2013.06.015. Epub 2013 Aug 1. Erratum in: Mol Immunol. 2015 Jan;99(1):604.

PMID:
23911405
12.

Functional analysis of mouse ficolin-B and detection in neutrophils.

Hunold K, Weber-Steffens D, Runza VL, Jensenius JC, Männel DN.

Immunobiology. 2012 Oct;217(10):982-5. doi: 10.1016/j.imbio.2012.01.013. Epub 2012 Jan 16.

PMID:
22459270
13.

Ficolins: novel pattern recognition molecules of the innate immune response.

Runza VL, Schwaeble W, Männel DN.

Immunobiology. 2008;213(3-4):297-306. doi: 10.1016/j.imbio.2007.10.009. Epub 2007 Nov 28. Review.

PMID:
18406375
14.

Localization of the mouse defense lectin ficolin B in lysosomes of activated macrophages.

Runza VL, Hehlgans T, Echtenacher B, Zähringer U, Schwaeble WJ, Männel DN.

J Endotoxin Res. 2006;12(2):120-6.

PMID:
16690015
15.

Screening of catalytically active microorganisms for the synthesis of 6-modified purine nucleosides.

Trelles JA, Valino AL, Runza V, Lewkowicz ES, Iribarren AM.

Biotechnol Lett. 2005 Jun;27(11):759-63.

PMID:
16086256

Supplemental Content

Support Center